Hermetica Superfood Encyclopedia
The Short Answer
Quassia amara's primary bioactives are quassinoids—chiefly quassin and 2-methoxycanthin-6-one—which exert antiulcer effects via H2 receptor antagonism and prostaglandin-mediated cytoprotection, and antimalarial effects by targeting chloroquine-resistant Plasmodium falciparum. In rat models, oral extract doses of 800 mg/kg provided 77–85% cytoprotective efficacy against indomethacin-induced gastric ulcers, representing the strongest quantified outcome in the current literature.
CategoryHerb
GroupSoutheast Asian
Evidence LevelPreliminary
Primary KeywordQuassia amara benefits
Quassia — botanical close-up
Health Benefits
**Gastric Cytoprotection**
Quassinoids and 2-methoxycanthin-6-one inhibit both basal and histamine-stimulated gastric acid secretion through H2 receptor antagonism, with rat studies demonstrating 77–85% protection against indomethacin-induced ulceration at 800 mg/kg oral extract.
**Antimalarial Activity**
Quassinoids including quassin exhibit potent activity against chloroquine-resistant strains of Plasmodium falciparum in vitro, offering a potential pharmacological scaffold for drug-resistant malaria where conventional treatments have failed.
**Antitumor Potential**
The quassinoid quassimarin inhibited P388 murine leukemia cells with an ED50 of 0.26 ± 0.012 µg/ml across multiple human tumor cell lines including KB and A-549, achieving approximately 81% inhibition at 200 mg/kg extract in preclinical models.
**Anti-inflammatory Effects**
Brucein B, a quassinoid constituent, inhibits leukocyte-endothelial adhesion, a critical early step in inflammatory cascades, suggesting utility in conditions driven by immune cell trafficking and vascular inflammation.
**Antifertility/Endocrine Modulation**
Quassin dose-dependently suppresses both basal and LH-stimulated testosterone secretion from rat Leydig cells across a concentration range of 50–250 µg/ml methanol extract, indicating significant gonadotropic axis interference.
**Bitter Tonic and Digestive Aid**
The profound bitterness of quassinoids stimulates vagally mediated digestive secretions, promoting bile flow, enzymatic activity, and appetite, consistent with traditional Jamu and European herbal pharmacopoeia use as a stomachic.
**Antipyretic and Antiparasitic Use**
Traditional and ethnopharmacological records document Q. amara wood infusions for fever reduction and intestinal parasite management across South American and West African populations, supported by plausible biological activity against protozoa and helminths.
Origin & History
Natural habitat
Quassia amara is a small tropical tree native to the rainforests of northern South America, particularly Suriname, Brazil, Colombia, and Panama, where it thrives in humid lowland forest edges and riverbanks at low elevations. The tree was named after Graman Quassi, an enslaved Surinamese man who revealed its medicinal uses to Europeans in the 18th century. It has since been introduced to West Africa, Southeast Asia including Indonesia, and parts of the Caribbean, where it is cultivated semi-wild or harvested from natural stands for its intensely bitter wood and bark.
“Quassia amara was introduced to European medicine in the mid-18th century after Graman Quassi, a Surinamese healer, used it to treat malaria and tropical fevers, leading Swedish botanist Carl Linnaeus to name the genus in his honor around 1761. In South American indigenous traditions, particularly among communities in Suriname, Guyana, and Brazil, the wood was prepared as a cold infusion called 'bitterwood tea' for fevers, intestinal worms, digestive complaints, and as an insecticide applied topically for lice. In Indonesian Jamu—the traditional herbal medicine system of the archipelago—Quassia preparations are integrated into bitter tonic formulas targeting fever management and malaria-associated symptoms, aligning with its demonstrated bioactivity against Plasmodium species. European pharmacopoeias formally recognized Quassia wood (Lignum Quassiae) as an official bitter tonic well into the 20th century, and it was historically used as a non-alcoholic flavoring substitute for hops in brewing due to its intense bitterness.”Traditional Medicine
Scientific Research
The evidence base for Quassia amara consists entirely of in vitro cell studies and animal model experiments, with no published human randomized controlled trials identified as of the current literature review. The most robust pharmacological data derive from rat indomethacin-ulcer models demonstrating statistically significant ulcer inhibition (P<0.01) at oral doses of 200–800 mg/kg extract, and from in vitro cytotoxicity assays showing an ED50 of 0.26 µg/ml against multiple human tumor cell lines. Antimalarial activity against chloroquine-resistant Plasmodium falciparum has been documented in vitro but has not been validated in clinical or even mammalian infectious disease models. The overall quality of evidence is low by contemporary standards—studies lack sample size reporting, dose-response relationships in humans are unknown, and bioavailability data are absent—placing Q. amara firmly in the preliminary-preclinical evidence tier.
Preparation & Dosage
Traditional preparation
**Traditional Wood Infusion**
1–2 g) steeped in 150–200 mL cold or hot water for several hours; consumed as a bitter tonic 2–3 times daily before meals in South American and Indonesian Jamu traditions
Chips or shavings of dried Q. amara wood (.
**Methanol/Hydroalcoholic Extract (Research Grade)**
200–800 mg/kg in rat studies; no human-equivalent dose established; rough allometric scaling suggests human equivalents would fall far below animal doses but remain unvalidated
Used at .
**Isolated Quassin/2-Methoxycanthin-6-one**
1–4 mg/kg (alkaloid) and 5–20 mg/kg (extract); oral doses of 12
Animal i.p. doses of .5–50 mg/kg (alkaloid); these figures are not transferable to human supplementation guidelines.
**Standardized Tincture (1
1–2 mL per dose, though no pharmacopeial standardization for quassin content has been universally adopted
5, 25% ethanol)**: Available in some European herbal traditions at .
**Timing**
Traditionally administered before meals to maximize bitter-tonic digestive stimulation; no clinical timing data exist.
**Standardization Note**
No internationally recognized standardization percentage for quassinoid content has been established; commercial preparations vary widely in potency.
Nutritional Profile
Quassia amara wood and bark are not consumed as a food or nutritional source; their phytochemical profile is dominated by pharmacologically active secondary metabolites rather than macronutrients or essential micronutrients. Primary phytochemicals include quassinoids: quassin, neoquassin, 18-hydroxyquassin, and quassimarin, present at varying concentrations depending on plant part, season, and geography. Alkaloids include 2-methoxycanthin-6-one, 1-vinyl-4,8-dimethoxy-β-carboline, 1-methoxycarbonyl-β-carboline, and 3-methylcantin-2,6-dione; triterpenes, flavonoids, and steroids are also present. In related Quassia species (Q. undulata seeds), antinutritional factors have been quantified: phytic acid at 951.67 mg/100g, oxalates at 636.3 mg/100g, and cyanogenic glycosides at 139.7 mg/100g, indicating that seeds of related species carry significant antinutritional loads not appropriate for dietary consumption. Fatty acids including arachidic acid (4.1–10.45%) and linolenic acid (~0.3%) have been identified in seed fractions of related species. Bioavailability of quassinoids from aqueous infusions is assumed to be moderate given their polar nature, but pharmacokinetic data in humans are entirely absent.
How It Works
Mechanism of Action
Quassin and 2-methoxycanthin-6-one act as H2 receptor antagonists at parietal cells of the gastric mucosa, reducing histamine-driven proton pump activation and decreasing acid secretion volume and gastric pH in a manner that is additive with cimetidine. Additionally, these compounds stimulate prostaglandin E2 synthesis in gastric epithelium, counteracting NSAID-induced mucosal damage by restoring cytoprotective prostanoid signaling pathways. At the cellular level, quassinoids interfere with mitochondrial electron transport and protein synthesis in parasitic organisms, which likely underlies both the antimalarial activity against Plasmodium falciparum and the antitumor cytotoxicity observed against leukemia and carcinoma lines. Brucein B modulates NF-κB-related inflammatory signaling by suppressing integrin-mediated leukocyte adhesion to vascular endothelium, reducing the amplification of acute and chronic inflammatory responses.
Clinical Evidence
No human clinical trials examining Quassia amara's efficacy or safety have been identified; all quantified outcomes originate from animal and cell-based studies. The antiulcer rat model data are the most methodologically developed, demonstrating 77–85% cytoprotection and significant acid secretion reduction at high oral doses, though extrapolation to human therapeutic dosing is not possible without pharmacokinetic bridging studies. In vitro antitumor results (81% P388 inhibition, ED50 ~0.26 µg/ml) are promising but represent an early preclinical stage with no subsequent human trial progression documented. Confidence in clinical benefit for any indication must be rated as very low, and practitioners should regard Q. amara as a traditional botanical with bioactive potential rather than a clinically validated therapeutic agent.
Safety & Interactions
No formal human toxicity profiles, no-observed-adverse-effect levels (NOAELs), or maximum safe doses have been established for Quassia amara in clinical populations, as all safety data derive from animal experiments in which tested doses did not produce overt toxicity signs. The testosterone-suppressing activity of quassin at 50–250 µg/ml in rat Leydig cell models represents a meaningful safety signal for men of reproductive age, and the herb is contraindicated in individuals seeking to preserve fertility or androgen function. Drug interactions of particular concern include additive acid suppression when co-administered with H2 receptor antagonists such as cimetidine or ranitidine, and a pharmacodynamic interaction with NSAIDs via opposing prostaglandin pathways. Pregnancy and lactation are absolute contraindications given the absence of safety data, the antifertility pharmacology of quassin, and the presence of potentially toxic alkaloids; related-species seeds contain substantial oxalate and cyanogenic glycoside levels that further caution against unsupervised consumption.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Quassia amara L.AmargoBitterwoodSimarouba amaraQuassia
Frequently Asked Questions
What is Quassia amara used for traditionally?
Traditionally, Quassia amara wood and bark have been used as a bitter tonic for digestive complaints, fever reduction, malaria, and intestinal parasite management across South America, West Africa, and Southeast Asian Jamu traditions. The wood is prepared as a cold infusion or decoction and consumed before meals to stimulate digestive secretions; it has also been used topically as a lice treatment. No human clinical trials have validated these traditional uses, though animal studies support biological plausibility for the antiulcer and antimalarial applications.
Does Quassia amara work for malaria?
In vitro studies have confirmed that quassinoids from Quassia amara exhibit activity against chloroquine-resistant strains of Plasmodium falciparum, the parasite responsible for the most deadly form of malaria. However, this evidence is limited to cell culture experiments; no human or animal infectious disease trials have been published to confirm efficacy or safe dosing in actual malaria treatment. Until clinical trials are conducted, Quassia amara cannot be recommended as a replacement for or adjunct to established antimalarial drug regimens.
Is Quassia amara safe to take as a supplement?
Safety data for Quassia amara in humans are essentially absent; all toxicology information comes from animal experiments that did not identify overt toxicity at tested doses. However, meaningful concerns exist: quassin suppresses testosterone production in rat Leydig cells at relatively low concentrations (50–250 µg/ml), and the alkaloid and quassinoid content carry theoretical risks for hematological and hepatic effects with prolonged use. Quassia amara is contraindicated during pregnancy, lactation, and in men with fertility concerns, and should not be used without medical supervision given the lack of established safe human doses.
What is the active compound in Quassia amara?
The primary active compounds in Quassia amara are quassinoids—bitter triterpenoid-derived secondary metabolites—most notably quassin, neoquassin, and quassimarin, as well as the β-carboline alkaloid 2-methoxycanthin-6-one. Quassin is responsible for the plant's extreme bitterness and mediates the testosterone-suppressing and antiparasitic activities, while 2-methoxycanthin-6-one has demonstrated antiulcer activity via H2 receptor antagonism at 4 mg/kg intraperitoneal dosing in rats. Both compound classes have shown cytotoxic activity against cancer cell lines in vitro, with an ED50 of approximately 0.26 µg/ml across several human tumor lines.
What is the recommended dose of Quassia amara?
No standardized or clinically validated dose for Quassia amara has been established in humans; all dosing references come from animal pharmacology studies. Rat studies used oral extract doses of 200–800 mg/kg and isolated 2-methoxycanthin-6-one at 12.5–50 mg/kg orally, which do not translate directly to human dosing without pharmacokinetic data. Traditional preparations typically involve 1–2 g of dried wood chips infused in cold water and consumed as a bitter tonic before meals, but practitioners should exercise caution and consult a healthcare provider before use given the absence of human safety and efficacy data.
Does Quassia amara interact with acid-reducing medications like H2 blockers or proton pump inhibitors?
Quassia amara contains quassinoids that work similarly to H2 receptor antagonists by reducing gastric acid secretion, which may potentiate the effects of prescription acid-reducing medications like famotidine or omeprazole. Concurrent use could theoretically increase the risk of insufficient stomach acid for nutrient absorption and pathogen defense, so consultation with a healthcare provider is recommended before combining Quassia amara with these medications.
Is Quassia amara safe to use during pregnancy and breastfeeding?
There is insufficient clinical safety data on Quassia amara use during pregnancy and breastfeeding, and traditional use for digestive and antimalarial purposes suggests physiologically active compounds that warrant caution. Pregnant and nursing women should avoid Quassia amara supplementation unless explicitly approved by their healthcare provider, as quassinoids may affect gastric function in ways that could impact fetal or infant development.
What does current research show about Quassia amara's effectiveness for stomach ulcers compared to standard treatments?
Animal studies demonstrate that Quassia amara extract provides 77–85% protection against indomethacin-induced ulcers at high doses (800 mg/kg), suggesting significant gastric cytoprotective potential through H2 receptor antagonism. However, robust human clinical trials comparing Quassia amara directly to standard ulcer treatments like H2 blockers or PPIs are limited, making it premature to recommend it as a primary ulcer therapy without professional medical guidance.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w quassia-amara-quassia-amara-l curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
